ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0246

Comorbidity Clusters in Patients with Rheumatoid Arthritis Predict Survival Prognosis

Cynthia Crowson1, Tina Gunderson2, John Davis2, Elena Myasoedova2, Vanessa Kronzer2, Caitrin Coffey2, Bradly Kimbrough3 and Elizabeth Atkinson2, 1Mayo Clinic, Eyota, MN, 2Mayo Clinic, Rochester, MN, 3Mayo Clinic Rochester, Rochester, MN

Meeting: ACR Convergence 2022

Keywords: Comorbidity, Mortality, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Comorbidities are common in patients with rheumatoid arthritis (RA), but there is little information regarding the occurrence of distinct comorbidity patterns in patients with RA and how these patterns impact outcomes. We aimed to examine clusters of patients with RA based on comorbidities and the impact of these clusters on mortality.

Methods: In this retrospective, population-based study, residents of a geographically well-defined area with prevalent RA on 1-1-2015 were identified from a comprehensive medical record linkage system. Patients were followed for vital status until death, last contact or 12-31-2021. Diagnostic codes were retrieved for 5-years prior to the prevalence date. Using 2 codes at least 30 days apart, a previously described set of 55 comorbidities were defined. Latent class analysis (LCA) was used to cluster patients based on comorbidity patterns, and the optimal number of clusters was determined by Bayesian Information Criteria. Standardized mortality ratios (SMR) were used to assess differences in mortality across the clusters.

Results: A total of 1643 patients with prevalent RA (72% female; 94% white; median age 64 years, median RA duration 7 years) were studied. Comorbidities were present in 1548 (94%) of the subjects with 5+ comorbidities present in 980 (59%) subjects.

LCA identified 4 clusters of patients. Although only comorbidities were used in the LCA, the clusters differed by age, sex, number of comorbidities, smoking status, body mass index (BMI) and RF/ anti-CCP positivity (Table 1). Cluster 1 (n=686) included younger patients (median age 55 years) who were less likely to smoke and had fewer comorbidities than those in the other clusters. At the other extreme, cluster 4 (n=134) included older patients (median age 77 years) with 6+ comorbidities who were more likely to have smoked. Cluster 2 (n=200) included younger patients (median age 60 years) with 6+ comorbidities and high BMI, while cluster 3 (n=623) included the remaining patients with comorbidities also common in the general population (median age 72 years, 3+ comorbidities consisting mainly of hypertension, hyperlipidemia and back problems). Cluster 1 had no increased mortality based on US lifetables (SMR 0.8; 95% confidence interval [CI: 0.55-1.1). Cluster 4 had the worst survival (SMR 3.5; 95% CI 2.8-4.4). Cluster 2 also had poor survival (SMR 1.6; 95% CI 1.03-2.2), while the poor survival in cluster 3 was less pronounced (SMR 1.2; 95% CI 0.99-1.4).

Conclusion: Clustering of patients with RA into subgroups based on comorbidity profiles identified distinct groups that exhibited differing survival outcomes compared with expected mortality in the general population. This demonstrates comorbidities congregate in some patients, leading to poor prognosis, while other patients may experience fewer comorbidities and may have a better survival experience than people without RA. Comorbidity patterns may hold the key to moving beyond a one-size-fits-all perspective of survival for patients with RA. Further research is needed to elucidate the contributions of RA disease activity and comorbidity patterns in the long-term prognosis of RA.

Supporting image 1


Disclosures: C. Crowson, None; T. Gunderson, None; J. Davis, Pfizer; E. Myasoedova, None; V. Kronzer, None; C. Coffey, None; B. Kimbrough, None; E. Atkinson, None.

To cite this abstract in AMA style:

Crowson C, Gunderson T, Davis J, Myasoedova E, Kronzer V, Coffey C, Kimbrough B, Atkinson E. Comorbidity Clusters in Patients with Rheumatoid Arthritis Predict Survival Prognosis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/comorbidity-clusters-in-patients-with-rheumatoid-arthritis-predict-survival-prognosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comorbidity-clusters-in-patients-with-rheumatoid-arthritis-predict-survival-prognosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology